Natera

Natera is not an investment firm but a molecular diagnostics company. Investment decisions are made by the CEO and board, prioritizing clinical trial funding and commercial expansion. The firm does not manage third-party capital or operate as a family office.

Natera is a diagnostics company, not a fund. It does not make fund commitments or direct investments as a limited partner. Its capital deployment is entirely operational—R&D, laboratory infrastructure, and commercial sales.

Natera operates in three clinical areas: oncology (using the Signatera™ ctDNA test for molecular residual disease monitoring), women's health (Panorama™ noninvasive prenatal testing), and organ health (Prospera™ donor-derived cfDNA for transplant rejection monitoring). These are supported by a pipeline of large prospective studies.

Natera is a publicly traded company (NASDAQ: NTRA). It has no disclosed connection to any single-family or multi-family office. Founder Matthew Rabinowitz may have personal wealth structures, but those are not publicly linked to the firm's operations.

Natera is a public corporation. Its market capitalization is derived from public equity investors. Founder Matthew Rabinowitz's wealth originates from his equity stake in the company, but the firm itself does not disclose private wealth origins.

Natera’s website describes a sustainability program focused on reducing environmental impact in its labs, offices, and supply chain. The firm does not publicly disclose a separate philanthropic foundation. There is no evidence of a corporate foundation or donor-advised fund directly linked to the company.

Natera does not co-invest with external general partners. The firm is a diagnostics business, not an investment vehicle. Its partnerships are clinical and commercial in nature—such as the May 2026 collaboration with Diakonos Oncology—and do not involve co-investment structures.